Status:
RECRUITING
Haemoadsorption During Heart Transplantation
Lead Sponsor:
Medical University of Vienna
Conditions:
Heart Transplantation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To investigate whether the use of haemoadsorption (HA) on cardiopulmonary bypass during heart transplantation (HTX) has an effect on circulating cytokine levels for the first 120 hours after HTX and i...
Eligibility Criteria
Inclusion
- Adult patients undergoing heart transplantation
Exclusion
- Declined informed consent
- Age \< 18 years#
- Receiving antileukocyte drugs
- Receiving TNF-α Blockers, immunosuppressive drugs (e.g. tocilizumab)
- DCD
- Ex-vivo perfusion
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05270902
Start Date
September 1 2022
End Date
June 30 2026
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Divison of Cardiac Thoracic Vascular Anaesthesia and Intensive Care, Medical University of Vienna
Vienna, Vienna, Austria, 1090